Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.0K
5.0K
Vaccine Production01:23

Vaccine Production

144
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
144
Vaccines01:21

Vaccines

98
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
98
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same author

Influenza coinfection inhibits control of mycobacterial infection in a human challenge model.

Nature communications·2026
Same author

Predicting trajectories of illness using RNA velocity of whole blood.

Nature communications·2026
Same author

VizCOM: A Novel Tool for Advanced Visualization and Analysis of Cardiac Optical Mapping Data.

Computing in cardiology·2026
Same author

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Comparative cross-species transcriptomics during RSV infection identifies targets to treat RSV disease.

The Journal of infection·2026

Related Experiment Video

Updated: May 4, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.6K

Current concepts and progress in RSV vaccine development.

Aleks K Guvenel1, Christopher Chiu, Peter Jm Openshaw

  • 1Centre for Respiratory Infection, National Heart and Lung Institute, Imperial College London, W2 1PG , UK.

Expert Review of Vaccines
|January 11, 2014
PubMed
Summary
This summary is machine-generated.

Developing new vaccines for Respiratory Syncytial Virus (RSV) is crucial for public health. Advances in immunology and vaccine technology offer promising strategies to combat RSV disease in vulnerable populations.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.3K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.3K

Related Experiment Videos

Last Updated: May 4, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.6K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.3K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.3K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Respiratory syncytial virus (RSV) causes significant morbidity and mortality globally, particularly in children and the elderly.
  • Past vaccine development efforts faced challenges, including poor immune responses and disease enhancement with formalin-inactivated vaccines.
  • Significant progress in understanding RSV immunology and advancements in vaccine technologies have renewed hope for effective interventions.

Purpose of the Study:

  • To review the current challenges and recent advances in the development of vaccines against Respiratory Syncytial Virus (RSV).
  • To explore promising vaccine approaches tailored for different vulnerable populations, including children, pregnant women, and older adults.
  • To propose a multi-pronged prevention strategy to reduce community transmission and disease burden of RSV.

Main Methods:

  • Review of existing literature on RSV pathogenesis, immunology, and vaccine development history.
  • Analysis of current promising vaccine candidates and technologies.
  • Synthesis of findings to propose a comprehensive prevention strategy.

Main Results:

  • Several novel vaccine candidates targeting RSV are in development, utilizing diverse platforms and strategies.
  • Different vaccine approaches show potential for specific age groups and risk populations.
  • A coordinated, multi-pronged approach to RSV prevention is likely necessary to impact community spread.

Conclusions:

  • Recent scientific and technological advances provide a strong foundation for developing effective RSV vaccines.
  • Targeted vaccination strategies for different populations are essential for comprehensive RSV control.
  • A combination of vaccination strategies may be key to reducing the overall impact of RSV disease.